Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CBUS
CBUS logo

CBUS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cibus Inc (CBUS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.500
1 Day change
6.38%
52 Week Range
4.190
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CBUS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is sitting near its pivot with weak near-term trend confirmation, no recent news catalyst, no supportive insider/hedge fund activity, and no strong proprietary buy signal. The options market shows bullish positioning, but the lack of volume and the extremely elevated implied volatility make this a poor entry for an impatient investor seeking straightforward long-term upside. Overall, the best call today is to hold and wait for clearer momentum or a better setup.

Technical Analysis

Price closed at 1.385, essentially flat to slightly down versus the previous close of 1.39. The technical picture is neutral to slightly weak: RSI_6 at 55.17 shows no strong momentum, MACD histogram is positive at 0.0202 but contracting, and moving averages are converging, which points to indecision rather than a strong uptrend. The pivot is 1.384, almost exactly where price is trading, with resistance at 1.475 and 1.532 and support at 1.292 and 1.235. That suggests the stock is range-bound and not breaking out convincingly. The pattern-based forecast also leans bearish in the medium term, with a projected -7.73% move over the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options positioning is heavily call-skewed, which normally signals bullish sentiment, but the context is mixed. Open interest put-call ratio of 0.08 is very low, indicating strong call dominance. However, option volume is extremely light today, with only 2 contracts traded and a put-call volume ratio of 0.0, so the bullish sentiment is not being confirmed by active trading. Implied volatility is very high at 579.94, with IV percentile at 98.81 and IV rank at 55.21, which reflects expensive options and elevated uncertainty rather than clean directional conviction. Net: sentiment is bullish on paper, but not persuasive enough to justify an aggressive buy.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
8

Positive Catalysts

  • ["Options positioning is strongly call-biased based on open interest.", "MACD histogram remains above zero, so short-term momentum has not fully turned negative.", "Price is holding near the pivot level, which can act as a base if buyers step in."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no clear event-driven catalyst.", "No significant hedge fund accumulation and no insider buying trend.", "No recent AI Stock Picker or SwingMax signal.", "Extremely high implied volatility makes the setup less attractive for a beginner long-term investor.", "Pattern-based trend outlook is weak over the next month.", "Recent price action is flat to slightly negative and not showing breakout strength."]

Financial Performance

No usable financial snapshot was available because of a data error, so latest-quarter revenue and earnings growth cannot be assessed from the provided data. Based on the information available, there is no evidence here of a strong latest-quarter fundamental catalyst to support a fresh long-term purchase.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street upgrade/downgrade momentum to support the stock. From the available evidence, the Wall Street view appears neutral to cautious rather than strongly bullish, with no clear pros-vs-cons edge in favor of buying today.

Wall Street analysts forecast CBUS stock price to rise
3 Analyst Rating
Wall Street analysts forecast CBUS stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.410
sliders
Low
15
Averages
18.67
High
25
Current: 1.410
sliders
Low
15
Averages
18.67
High
25
Jefferies
Hold
maintain
$3
AI Analysis
2026-03-25
Reason
Jefferies
Price Target
$3
AI Analysis
2026-03-25
maintain
Hold
Reason
Jefferies raised the firm's price target on Cibus to $3 from $1.90 and keeps a Hold rating on the shares. With the capital raise in January and cost cutting measures, Cibus aims tot have ample cash for operating expenses and capex through at least 3Q26, the analyst tells investors in a research note. With EU genetic engineering regulations likely finalized in Q2, the firm expects a pickup in customer engagement in trait insertion, single-cell cloning, field trial efficiency solutions, and biofragrance production.

People Also Watch